U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

FGF19 Gene Amplification

MedGen UID:
1654236
•Concept ID:
C4724140
•
Cell or Molecular Dysfunction
Synonyms: FGF-19 Gene Amplification; FGF19 Amplification; Fibroblast Growth Factor 19 Gene Amplification; Fibroblast Growth Factor-19 Gene Amplification; HBGF-1 Gene Amplification

Definition

A molecular genetic abnormality indicating the presence of multiple copies of the FGF19 gene. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVFGF19 Gene Amplification

Professional guidelines

PubMed

Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H, Kubo M, Yamashita N, Yamamoto H, Kai M, Kajihara A, Yamada M, Kurata K, Kaneshiro K, Harada Y, Hayashi S, Shimazaki A, Mori H, Akiyoshi S, Oki E, Oda Y, Baba E, Mori M, Nakamura M
Cancer Med 2021 Jan;10(2):529-539. Epub 2020 Dec 4 doi: 10.1002/cam4.3619. PMID: 33274848Free PMC Article
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
Kaibori M, Sakai K, Ishizaki M, Matsushima H, De Velasco MA, Matsui K, Iida H, Kitade H, Kwon AH, Nagano H, Wada H, Haji S, Tsukamoto T, Kanazawa A, Takeda Y, Takemura S, Kubo S, Nishio K
Oncotarget 2016 Aug 2;7(31):49091-49098. doi: 10.18632/oncotarget.10077. PMID: 27384874Free PMC Article
Genome-wide screening for genetic alterations in esophageal cancer by aCGH identifies 11q13 amplification oncogenes associated with nodal metastasis.
Ying J, Shan L, Li J, Zhong L, Xue L, Zhao H, Li L, Langford C, Guo L, Qiu T, Lu N, Tao Q
PLoS One 2012;7(6):e39797. Epub 2012 Jun 25 doi: 10.1371/journal.pone.0039797. PMID: 22761904Free PMC Article

Recent clinical studies

Etiology

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
Kim JY, Jung J, Kim KM, Lee J, Im YH
Cancer Med 2023 Jun;12(11):12438-12451. Epub 2023 Apr 20 doi: 10.1002/cam4.5953. PMID: 37081749Free PMC Article
Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H, Kubo M, Yamashita N, Yamamoto H, Kai M, Kajihara A, Yamada M, Kurata K, Kaneshiro K, Harada Y, Hayashi S, Shimazaki A, Mori H, Akiyoshi S, Oki E, Oda Y, Baba E, Mori M, Nakamura M
Cancer Med 2021 Jan;10(2):529-539. Epub 2020 Dec 4 doi: 10.1002/cam4.3619. PMID: 33274848Free PMC Article
Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104.
Li F, Li Z, Han Q, Cheng Y, Ji W, Yang Y, Lu S, Xia W
Oncogene 2020 Apr;39(17):3507-3521. Epub 2020 Feb 28 doi: 10.1038/s41388-020-1227-2. PMID: 32111983Free PMC Article
YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
Dai H, Shao YW, Tong X, Wu X, Pang J, Feng A, Yang Z
Cancer Med 2020 Mar;9(5):1628-1637. Epub 2019 Dec 18 doi: 10.1002/cam4.2761. PMID: 31851786Free PMC Article
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
Kaibori M, Sakai K, Ishizaki M, Matsushima H, De Velasco MA, Matsui K, Iida H, Kitade H, Kwon AH, Nagano H, Wada H, Haji S, Tsukamoto T, Kanazawa A, Takeda Y, Takemura S, Kubo S, Nishio K
Oncotarget 2016 Aug 2;7(31):49091-49098. doi: 10.18632/oncotarget.10077. PMID: 27384874Free PMC Article

Diagnosis

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
Kim JY, Jung J, Kim KM, Lee J, Im YH
Cancer Med 2023 Jun;12(11):12438-12451. Epub 2023 Apr 20 doi: 10.1002/cam4.5953. PMID: 37081749Free PMC Article
Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H, Kubo M, Yamashita N, Yamamoto H, Kai M, Kajihara A, Yamada M, Kurata K, Kaneshiro K, Harada Y, Hayashi S, Shimazaki A, Mori H, Akiyoshi S, Oki E, Oda Y, Baba E, Mori M, Nakamura M
Cancer Med 2021 Jan;10(2):529-539. Epub 2020 Dec 4 doi: 10.1002/cam4.3619. PMID: 33274848Free PMC Article
Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.
Caruso S, Calatayud AL, Pilet J, La Bella T, Rekik S, Imbeaud S, Letouzé E, Meunier L, Bayard Q, Rohr-Udilova N, Péneau C, Grasl-Kraupp B, de Koning L, Ouine B, Bioulac-Sage P, Couchy G, Calderaro J, Nault JC, Zucman-Rossi J, Rebouissou S
Gastroenterology 2019 Sep;157(3):760-776. Epub 2019 May 4 doi: 10.1053/j.gastro.2019.05.001. PMID: 31063779
Gastric carcinoma with a gastrointestinal stromal tumor - A case report and literature review.
Liu S, Liu H, Dong Y, Wang F, Wang H, Chen J
Med Sci (Paris) 2018 Oct;34 Focus issue F1:15-19. Epub 2018 Nov 7 doi: 10.1051/medsci/201834f103. PMID: 30403169
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.
Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM
Gastroenterology 2015 Oct;149(5):1226-1239.e4. Epub 2015 Jun 20 doi: 10.1053/j.gastro.2015.05.061. PMID: 26099527

Therapy

The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody.
Liu C, Zhu S, Dong Y, Shao J, Liu B, Shen J
Front Immunol 2022;13:930096. Epub 2022 Jul 7 doi: 10.3389/fimmu.2022.930096. PMID: 35874743Free PMC Article
Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H, Kubo M, Yamashita N, Yamamoto H, Kai M, Kajihara A, Yamada M, Kurata K, Kaneshiro K, Harada Y, Hayashi S, Shimazaki A, Mori H, Akiyoshi S, Oki E, Oda Y, Baba E, Mori M, Nakamura M
Cancer Med 2021 Jan;10(2):529-539. Epub 2020 Dec 4 doi: 10.1002/cam4.3619. PMID: 33274848Free PMC Article
YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
Dai H, Shao YW, Tong X, Wu X, Pang J, Feng A, Yang Z
Cancer Med 2020 Mar;9(5):1628-1637. Epub 2019 Dec 18 doi: 10.1002/cam4.2761. PMID: 31851786Free PMC Article
Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.
Lang L, Teng Y
Cells 2019 Jan 9;8(1) doi: 10.3390/cells8010031. PMID: 30634399Free PMC Article
Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients.
Tan Q, Li F, Wang G, Xia W, Li Z, Niu X, Ji W, Yuan H, Xu Q, Luo Q, Zhang J, Lu S
Oncotarget 2016 Apr 5;7(14):18394-402. doi: 10.18632/oncotarget.7817. PMID: 26943773Free PMC Article

Prognosis

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
Kim JY, Jung J, Kim KM, Lee J, Im YH
Cancer Med 2023 Jun;12(11):12438-12451. Epub 2023 Apr 20 doi: 10.1002/cam4.5953. PMID: 37081749Free PMC Article
FGF19 promotes cell autophagy and cisplatin chemoresistance by activating MAPK signaling in ovarian cancer.
Zhu W, Huang M, Thakur A, Yan Y, Wu X
PeerJ 2023;11:e14827. Epub 2023 Feb 2 doi: 10.7717/peerj.14827. PMID: 36751636Free PMC Article
The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody.
Liu C, Zhu S, Dong Y, Shao J, Liu B, Shen J
Front Immunol 2022;13:930096. Epub 2022 Jul 7 doi: 10.3389/fimmu.2022.930096. PMID: 35874743Free PMC Article
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M, Crimini E, Giugliano F, Morganti S, Belli C, Curigliano G
Expert Rev Clin Pharmacol 2021 Oct;14(10):1233-1252. doi: 10.1080/17512433.2021.1947246. PMID: 34591728
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.
Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM
Gastroenterology 2015 Oct;149(5):1226-1239.e4. Epub 2015 Jun 20 doi: 10.1053/j.gastro.2015.05.061. PMID: 26099527

Clinical prediction guides

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
Kim JY, Jung J, Kim KM, Lee J, Im YH
Cancer Med 2023 Jun;12(11):12438-12451. Epub 2023 Apr 20 doi: 10.1002/cam4.5953. PMID: 37081749Free PMC Article
FGF19 promotes cell autophagy and cisplatin chemoresistance by activating MAPK signaling in ovarian cancer.
Zhu W, Huang M, Thakur A, Yan Y, Wu X
PeerJ 2023;11:e14827. Epub 2023 Feb 2 doi: 10.7717/peerj.14827. PMID: 36751636Free PMC Article
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M, Crimini E, Giugliano F, Morganti S, Belli C, Curigliano G
Expert Rev Clin Pharmacol 2021 Oct;14(10):1233-1252. doi: 10.1080/17512433.2021.1947246. PMID: 34591728
FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma.
Gao L, Lang L, Zhao X, Shay C, Shull AY, Teng Y
Oncogene 2019 Mar;38(13):2394-2404. Epub 2018 Dec 5 doi: 10.1038/s41388-018-0591-7. PMID: 30518874
Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development.
Uriarte I, Latasa MU, Carotti S, Fernandez-Barrena MG, Garcia-Irigoyen O, Elizalde M, Urtasun R, Vespasiani-Gentilucci U, Morini S, de Mingo A, Mari M, Corrales FJ, Prieto J, Berasain C, Avila MA
Int J Cancer 2015 May 15;136(10):2469-75. Epub 2014 Nov 6 doi: 10.1002/ijc.29287. PMID: 25346390

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...